AINE y riesgo cardiovascular
暂无分享,去创建一个
[1] T. Gill,et al. Cause for concern in the use of non-steroidal anti-inflammatory medications in the community -a population-based study , 2011, BMC family practice.
[2] K. Rothman,et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study , 2011, BMJ : British Medical Journal.
[3] Bruce Guthrie,et al. High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice , 2011, BMJ : British Medical Journal.
[4] L. Køber,et al. Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction: A Nationwide Cohort Study , 2011, Circulation.
[5] M. Egger,et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis , 2011, BMJ : British Medical Journal.
[6] Á. Mészáros,et al. Trends in the non‐steroidal anti‐inflammatory drug market in six Central–Eastern European countries based on retail information , 2010, Pharmacoepidemiology and drug safety.
[7] T. Macdonald,et al. Effect of ibuprofen on cardioprotective effect of aspirin , 2003, The Lancet.
[8] R Day,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[9] G. Singh,et al. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. , 1998, The American journal of medicine.